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VEGF isoforms have differential effects
on permeability of human pulmonary
microvascular endothelial cells
Khadija Ourradi1, Thomas Blythe1, Caroline Jarrett1, Shaney L. Barratt1, Gavin I. Welsh2 and Ann B. Millar1*
Abstract
Background: Alternative splicing of Vascular endothelial growth factor-A mRNA transcripts (commonly referred as
VEGF) leads to the generation of functionally differing isoforms, the relative amounts of which have potentially significant
physiological outcomes in conditions such as acute respiratory distress syndrome (ARDS). The effect of such isoforms on
pulmonary vascular permeability is unknown. We hypothesised that VEGF165a and VEGF165b isoforms would have
differing effects on pulmonary vascular permeability caused by differential activation of intercellular signal
transduction pathways.
Method: To test this hypothesis we investigated the physiological effect of VEGF165a and VEGF165b on Human
Pulmonary Microvascular Endothelial Cell (HPMEC) permeability using three different methods: trans-endothelial electrical
resistance (TEER), Electric cell-substrate impedance sensing (ECIS) and FITC-BSA passage. In addition, potential
downstream signalling pathways of the VEGF isoforms were investigated by Western blotting and the use of
specific signalling inhibitors.
Results: VEGF165a increased HPMEC permeability using all three methods (paracellular and transcellular) and
led to associated VE-cadherin and actin stress fibre changes. In contrast, VEGF165b decreased paracellular permeability
and did not induce changes in VE-cadherin cell distribution. Furthermore, VEGF165a and VEGF165b had differing effects
on both the phosphorylation of VEGF receptors and downstream signalling proteins pMEK, p42/44MAPK, p38 MAPK,
pAKT and peNOS. Interestingly specific inhibition of the pMEK, p38 MAPK, PI3 kinase and eNOS pathways blocked the
effects of both VEGF165a and VEGF165b on paracellular permeability and the effect of VEGF165a on proliferation/migration,
suggesting that this difference in cellular response is mediated by an as yet unidentified signalling pathway(s).
Conclusion: This study demonstrates that the novel isoform VEGF165a and VEGF165b induce differing effects on
permeability in pulmonary microvascular endothelial cells.
Keywords: Vascular permeability, Vascular endothelial growth factor (VEGF), Cell signalling
Background
VEGF was originally identified by its properties as both
a permogen and a mitogen, key elements in the function
of the alveolar-capillary membrane, leading to interest in
its role in many forms of lung disease particularly ARDS
[1–3]. We and others found that VEGF levels were com-
partmentalised between the alveolar space and the vas-
cular bed [4, 5]. Low levels of intrapulmonary VEGF
were found in patients with ARDS with increasing intra-
pulmonary VEGF levels associated with recovery [5]. In
contrast, plasma levels in patients with ARDS were ele-
vated compared with normal, at-risk, or ventilated con-
trol subjects, with falling levels associated with recovery
[6]. These data suggest that VEGF is beneficial in the al-
veolar space but detrimental in the vascular space. To
explore the significance of these observations, it is neces-
sary to understand the mechanisms that regulate VEGF
bioactivity. VEGF exerts its biological effect through spe-
cific receptors, VEGF-R1 and VEGF-R2 and co-receptors,
neuropilin-1 and neuropilin-2 [7]. In addition, alternative
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splicing of VEGF transcripts leads to the generation of sev-
eral functionally different isoforms [8, 9]. We have previ-
ously explored changes in VEGFxxx-isoforms and receptor
expression as mechanisms for regulating VEGF bioactivity
and suggested that both these factors may contribute [10]
but do not fully explain the reported contradictory find-
ings. The VEGFxxxb isoform family consists of peptides of
the same length as other forms but with a different C-
terminal six amino acids-SLTRKD rather than CDKPRR
[11]. The receptor binding and dimerisation domains are
intact, but VEGFxxxb stimulates a unique pattern of VEGF-
R2 tyrosine residue phosphorylation, contrasting with
those activated by conventional isoforms [9]. Two specific
isoforms, VEGF165a and VEGF165b isoforms were shown to
have contrasting effects on the epithelial and endothelial
sides of the alveolar-capillary membrane [12]. These data
suggest a pneumotropic effect which could be beneficial
within the alveolar space following ARDS. However, the
effect of these isoforms on vascular permeability another
key element of ARDS is unknown.
We hypothesised that VEGF165a and VEGF165b activate
different signalling pathways mediating cell permeability, a
potential explanation for the conflicting observations on
effects in the vascular space. To explore this theory, we
used three methods of assessing vascular barrier function
and found contrasting effects with VEGF165a increasing
permeability and VEGF165b decreasing permeability. We
then explored the relationship of downstream pathways to
these functional differences. We compared the effects of
specific signalling pathway inhibitors of MEK/p38MAPK/
PI3K and eNOS on permeability, cell migration and prolif-
eration to identify a mechanism by which increased per-
meability could be resolved whilst maintaining beneficial
cell proliferation and migration.
Methods
A detailed description of materials and methods is given
in the online data supplement.
Primary cell culture
Human Pulmonary microvascular endothelial cell (HPMEC)
cryopreserved from passage 2 (PromoCell, Heidelberg,
Germany) were cultured in endothelial cell basal medium
MV2 (C-22221, PromoCell, Germany) complemented with
supplement pack (C-39221, PromoCell, Germany) according
to manufacturer’s instructions.
For all experiments cells were grown to 80% conflu-
ence, quiesced (MV2 media only) and stimulated with
combinations of VEGF165a and VEGF165b (20 ng/ml as
considered physiologically relevant in circulating plasma)
[4, 6] in the presence or absence of specific signalling
pathway inhibitors (U0126, SB203580, LY294002 (Cell
Signalling, UK) or L-NAME (Calbiochem, UK).
Measurement of TEER by Endohm
Measurement of trans-endothelial electrical resistance
(TEER) of the cell monolayer was performed using an
Endohm 12 electrode chamber and an endothelial volt/
ohm meter EVOM2 (World precision Instruments,
USA) as previously described by Bevan and al [13].
ECIS
Cells were plated at 20000 cells/cm2 into 8-well arrays
(8W10E+; Wolf laboratories Ltd). Data was automatically
and continuously collected every 2 min and recorded by
computer. Experiments were performed after cells reached
confluence with basal TEER values > 1500 Hz.
FITC-BSA passage
Transendothelial permeability to macromolecules was
assessed by the passage of FITC-conjugated BSA (relative
molecular mass 66,000) across cell monolayers in tissue
culture inserts as previously described [14].
Scratch assay (Migration and proliferation)
Cells were seeded with 100 μl of cell suspension (5 × 105
cells/ml) in an Ibidi culture-chamber (Ibidi GmbH Mun-
ich, Germany). Cells were pre-incubated with or without
inhibitor for 1 hour before removal of the chamber.
Cells were then incubated in MV2 medium alone or
MV2 medium with 20 ng/ml of recombinant protein
VEGF165a or VEGF165b. Images were captured and ana-
lysed at 0 and 24 h.
Western blotting analysis
Cell lysates were separated on sodium dodecyl sulphate–
polyacrylamide gel electrophoresis (SDS-PAGE) and
immunoblotted. Blots were blocked with 5% bovine serum
albumin (BSA) (Fischer Scientific UK,) and incubated
overnight at 4 °C with primary antibodies
Immunocytochemistry
HPMEC were stimulated with 100 ng/ml of VEGF165a,
VEGF165b, VEGF165a + b or without any stimulation (con-
trol) for 10 min. They were then fixed, permeabilised and
immunostained for VE-cadherin (Sigma, UK) and Alexa
Fluor® 568 Phalloidin (Invitrogen, UK) for staining actin
structures.
Results
VEGF165a increases and VEGF165b decreases permeability
in HPMEC
A number of techniques have been described to assess
endothelial barrier function [15]. The barrier properties of
endothelial cell junctions can be directly measured by
TEER that has been shown to be indirectly correlated with
both adherens and tight junctions within a confluent
monolayer [16, 17]. We measured the TEER of HPMEC
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monolayers. VEGF165a significantly reduced the cell
resistance (increased permeability) **p < 0.01, from 45 min
onwards, in contrast, VEGF165b significantly increased re-
sistance (decreased permeability) **p < 0.01 between 15 to
45 min compared with unstimulated control cells (Fig. 1a).
ECIS was utilised as another method to evaluate the ef-
fect of VEGF isoforms on cell permeability. A similar re-
sponse to that seen using the Endohm system was
observed for HPMEC. VEGF165a induced an increase in
cell monolayer permeability (***p < 0.001) in contrast to
VEGF165b which induced a significant decrease (*p < 0.05)
in the cell monolayer permeability (Fig. 1b).
The last experimental technique used to assess perme-
ability was FITC-coupled BSA passage. The permeability
of the HPMEC monolayer for FITC-BSA was monitored
every 15 min up to 90 min by measuring the fluores-
cence intensity of the medium in the lower compart-
ment. For unstimulated control cells, the level of BSA in
the lower compartment increased slowly over time in a
comparable manner to those treated with VEGF165b; no
significant difference was observed between them in
HPMEC (Fig. 1c). When the cells were cultured in the
presence of VEGF165a, a significant (*p < 0.05) time-
dependant increase in BSA permeability was detected
after 45 min and persisted for at least 90 min, suggesting
an increase in the cell monolayer permeability.
VEGF165a induces changes in VE-cadherin distribution
pattern and actin stress fibres in HPMEC compared to
VEGF165b
Changes in cell permeability are closely related to changes
in the cell-cell junction structures [18]. We went on to
analyse potential cytoskeleton remodelling induced by
VEGF isoforms. VE-cadherin has been particularly associ-
ated with endothelial cell adherens junctions but may also




Fig. 1 HPMEC stimulated with 20 ng/ml of VEGF165a, VEGF165b or without any stimulation (control). a Paracellular permeability was quantified by
TEER using endohm-12 system in HPMEC cultured in inserts. VEGF165a reduced resistance (increased permeability) *p < 0.05 (45 min onwards) and
VEGF165b increased resistance (decreased permeability) ***p < 0.001 (15 to 45 min) compared to control. b ECIS measurements on HPMEC show
that VEGF165a reduced the resistance (increased permeability) significantly***p < 0.001 in comparison to control; whereas VEGF165b had an opposite
effect with a significant increase (*p < 0.05) in the resistance (reduced permeability). Data expressed as a mean fold-change compared to control over
time. c The passage of FITC-coupled BSA across the monolayer of HPMEC was monitored over a period of 90 min. The fluorescence intensity of the
aliquots was quantified and data was expressed as cumulative FITC-BSA over time. Concentration of FITC-BSA in the lower chamber slowly increased
in both control cells and those stimulated with VEGF165b; in contrast cells stimulated with VEGF165a showed a significant increase in the passage of
FITC-BSA p < 0.01 after 60 min. Each experiment was performed in triplicate (n = 5-8). All data were analysed using two-way ANOVA and Bonferroni
post-test for multiple analysis and plotted as mean ± SEM
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Previously, a changed distribution to a zig-zag pattern in
VEGF165a treated human umbilical vascular endothelial
cells (HUVEC) was demonstrated using 100 ng/ml stimu-
lation [20]. We repeated this experiment using HPMEC
and showed similar results suggesting a significant
change in VE-cadherin distribution between the cells
stimulated with VEGF165a (Fig. 2a). Visible gaps ap-
peared between the cells with an apparent zig-zag pat-
tern of VE-cadherin distribution between adjacent cells.
In contrast, stimulation with the VEGF165b isoform in-
duced minimal change compared to untreated control
cells suggesting it did not induce VE-cadherin reorgani-
sation (Fig. 2a). In addition, changes in the actin struc-
ture were observed between the stimulated and the
unstimulated cells demonstrating an increase of stress
fibres across the cells and more actin filopodia with
VEGF165a. Again, in contrast, there was only a partial
induction of actin filaments in the cell periphery and
stress fibres by VEGF165b (Fig. 2b). These data led to
the hypothesis that VEGF165a and VEGF165b activate
different signalling pathways involved in permeability in
HPMEC.
VEGF-R2 has been reported to induce most down-
stream signalling effects through the tyrosine sites
tyr1175 and tyr1214 [21, 22]. These two tyrosine sites
play a crucial and direct role in the recruitment of
adaptor proteins that activate multiple signalling path-
ways such as proliferation, survival, migration and
permeability [23, 24]. Therefore, we studied VEGF iso-
form induced phosphorylation of those tyrosine sites in
HPMECs.
VEGF165a and VEGF165b induce differential
phosphorylation of the VEGF receptors at tyrosine 1175
and 1214 in HPMEC
VEGF-R2 phosphorylation at the tyrosine (tyr) 1175 site,
was significantly induced by VEGF165a at 5 min and
10 min (p < 0.05) in HPMEC (Fig. 3a) and returned to
control levels at 60 min post stimulation. In contrast,
VEGF165b stimulation did not induce significant phos-
phorylation at this site. Phosphorylation of VEGF-R2 at
the tyr1214 also reached a maximum at 5 min (p < 0.01)
with VEGF165a and subsequently decreased as repre-
sented in Fig. 3b. VEGF165b also induced significant
phosphorylation of tyr1214 site at 5 min (p < 0.05) in
HPMEC, in contrast to tyr1175. These differences in re-
ceptor phosphorylation support the potential for differ-
ential binding of other adaptor proteins in addition to
the previously reported changes in co-receptor binding
that has been shown to contribute to VEGF-induced
vascular permeability.
Having identified these phosphorylation differences we
wanted to identify specific pathways leading to cell per-
meability which is less well characterised than those of
other VEGF functional effects [7]. Further Western blot-
ting of HPMEC was undertaken, to investigate the effect
a
b
Fig. 2 a HPMEC were stimulated with 100 ng/ml of VEGF165a, VEGF165b or without stimulation (control) for 10 min. Then they were fixed, permeabilised
and immunostained for VE-cadherin. Control and VEGF165b: straight and linear distribution of VE-cadherin at the cell junctions were observed (see arrows).
VEGF165a: distribution of VE-cadherin in a zig-zag pattern with the appearance of gaps between the cells (see arrows) (magnification x40). b Actin and
nucleus staining in HPMEC in different conditions. Control: actin filament distributed mainly at the cell periphery between the cell-cell junctions. VEGF165a:
disruption of the cortical actin frame with filopodia and stress fibre formation across the cells (arrows). VEGF165b: mixed field with the appearance of actin
at the cell periphery and visible filopodia (magnification x40). (n= 5, representative image shown)
Ourradi et al. Respiratory Research  (2017) 18:116 Page 4 of 12
of VEGF isoforms on the phosphorylation of several pro-
teins previously suggested to be involved in specific
functional downstream cellular effects. In parallel, we
continued to use the Endohm assay to assess paracellu-
lar permeability and utilised the scratch assay combining
both migration and proliferation processes [25, 26] to
assess the specificity of the functional effect of individual
signalling pathway inhibitors.
Specific inhibition of pMEK1/2, p42/44MAPK and
p38MAPK induction by VEGF165a and VEGF 165b in
HPMEC does not have a differential effect on
permeability and migration/proliferation pathways
The MEK and mitogen activated protein kinase (MAPK)
pathways are among the most widely studied in VEGF
biology and considered to have critical roles in cell pro-
liferation and cell growth and differentiation [27, 28].
a
b
Fig. 3 Activation of VEGF-R2 was determined with a phospho-specific antibody recognising tyrosine (Y) site 1175 and site 1214 in graph (a) and
(b) respectively for cells stimulated with 20 ng/ml of VEGF165a (a), VEGF165b (b) or without stimulation (Ctl). Representative Western blot showing
the different conditions at 5, 10 and 60 min plus the loading control blot and densitometry (n = 5). All data were analysed using Kruskal-Wallis
with post hoc Dunn’s analysis and plotted as mean ± SEM
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We initially sought to determine whether inhibition of
these proteins would have a specific functional effect i.e.
inhibit proliferation/migration but not permeability as
previously suggested [29].
HPMEC showed a similar activation pattern of
pMEK1/2 and p42/44MAPK proteins with an increase
in the phosphorylation when treated with VEGF165a for
5 and 10 min that subsequently returned towards base-
line at 60 min (Fig. 4-a&b respectively). VEGF165b had a
delayed effect with significant phosphorylation of both
proteins occurring at 10 min. The pMEK1/2 phosphoryl-
ation in response to VEGF isoforms showed a significant
increase at 5 and 10 min (p < 0.01) for the cells stimu-
lated with VEGF165a compared to control. The max-
imum response was observed at 10 min for both
proteins. However, VEGF165b induced a significant in-
crease of pMEK1/2 and p42/44MAPK phosphorylation
at 10 min only. At 60 min the level of both phospho-
proteins in the stimulated cells returns toward the con-
trol levels.
U0126 is a compound reported to be a highly selective
inhibitor of MEK1 and MEK2 and utilised to block the
classical MAPK cascade in cells that leads to cell prolifera-
tion [30]. U0126 inhibited the permeability effects of both
VEGF165a and VEGF165b on HPMEC (Fig. 4c and d
respectively). VEGF165a, but not VEGF165b, induced a
significant increase in the cell migration into the “scratch”
(p = 0.004) in comparison to control (Fig. 4e) that was
inhibited byU0126. These data suggest that the MEK
pathway is activated by both VEGF165a and VEGF 165b but
any functional divergence must occur downstream.
In addition, phosphorylation of p38MAPK was assessed
as studies reported that VEGF stimulation on endothelial
cells, also lead to activation of the Cdc42/p38MAPK
pathway which triggers cytoskeletal modifications [31].
Similarly, to the other proteins studied, p38 MAPK
phosphorylation was significantly increased by VEGF165a
in HPMEC at 5 and 10 min (p < 0.05). Cells stimulated
with VEGF165b showed a significant increase in p38MAPK
phosphorylation (p = 0.04) compared to the untreated cells
(Fig. 5a). Nevertheless, this phosphorylation was transient
and returned to baseline levels by ten minutes. SB203580
is reported to specifically inhibit the activation of SAPK2/
p38 MAPK in cell-based assays but no other related kin-
ase protein including MAPK family members [30]. When
HPMEC were incubated with SB203580 (p38MAPK in-
hibitor) again there was inhibition of VEGF165a and
VEGF165b permeability effects (Fig. 5b and c). Cell prolif-
eration/migration into the “scratch” was significantly in-
creased (p = 0.002) only with VEGF165a stimulation and
this effect was inhibited by SB203580 (Fig. 5d).
Having identified significant differences in the activa-
tion kinetics of MEK, p42/44MAPK and p38MAPK by
VEGF165a compared to VEGF165b (that reflected changes
in permeability but not specific to it alone), we then
looked at the effect of VEGF isoforms on AKT also
known as protein kinase B (PKB) protein. AKT has been
shown to promote the proposed cell survival pathway
mediated by the activation of PI3-kinase protein kinase
[32] but it has been also associated with eNOS produc-
tion which is closely associated with permeability [33].
Specific inhibition of AKT induction by VEGF165a and
VEGF165b in HPMEC does not have a differential effect on
permeability and survival pathways
VEGF165b induces a rapid and robust phosphorylation of
pAKT at 5 min and 10 min (p < 0.01) in HPMEC with
maximal AKT phosphorylation detected at 5 min
(Fig. 5e). Stimulation with VEGF165a also induced a sig-
nificant phosphorylation of AKT at 5 (p < 0.05) and
10 min (p < 0.01) and returned to control levels at
60 min. LY294002 compounds is an inhibitor of phos-
phatidylinositol 3 kinase (PI3K) and inactivation of PI3K
have been reported to lead to dephosphorylation of Akt
that subsequently stop G1 cycle in cell growth and ul-
timately lead to cell apoptosis [34, 35]. Co-culture with
LY294002 to block AKT protein inhibited both the per-
meability effects of VEGF165a and VEGF165b on HPMEC
(Fig. 5 f and g). In contrast with the permeability assay
where the cell monolayer was stable over the experiment
(2 h), inhibition of AKT for long periods (24 h) induced
cell death so we were unable to undertake the scratch
assay as a migration/proliferation model.
Finally, we investigated the potential of the eNOS path-
way for differential effects. There is a significant body of
evidence to suggest that endothelial nitric oxide (synthe-
sised by eNOS) may have a crucial role in causing hyper-
permeability in response to pro-inflammatory agents such
as VEGF [36, 37]. Therefore, the effects of the different
VEGF isoforms on the eNOS phosphorylation in HPMEC
were studied.
Specific inhibition of eNOS induction by VEGF165a and
VEGF165b in HPMEC does not have a differential effect on
permeability and nitric oxide signalling pathways
In HPMEC, VEGF165a induced a significant increase in the
phosphorylation of eNOS at 5 (p < 0.05) and 10 min (p <
0.01) compared to untreated control cells (Fig. 6a).
VEGF165b did not induce changes in the phosphorylation
of eNOS at Ser 1177. L-NAME (NG-Nitro-L-arginine
Methyl Ester, Hydrochloride) is an analogue of L-
arginine required for the nitric oxide synthesis by the
vascular endothelium [38]. HPMEC pre-incubated with L-
NAME and treated with VEGF165a or VEGF165b did not
have any significant change in resistance compared to
control (Fig. 6b and c). In the scratch proliferation/migra-
tion model, L-NAME inhibited the migration effect in-
duced by VEGF165a, but no difference was observed for




Fig. 4 HPMEC were stimulated with 20 ng/ml of VEGF165a, VEGF165b or without any stimulation (Ctl/control). Representative western blots
showing VEGF stimulation at 5, 10 and 60 min plus loading control (α-tubulin) with densitometry (n = 3). a & b Western blot of phosphorylated
MEK1/2 (a) and phosphorylated p42/p44MAPK (b) in HPMEC. Stimulation with VEGF165a increased phosphorylation of MEK1/2 and p42/p44 at 5
and 10 min in contrast with VEGF165b which induced increased phosphorylation only at 10 min for both proteins. c & d Measurement of cells
resistance by Endohm system. Dotted lines correspond to cell pre-incubated with pMEK inhibitor UO126. UO126 inhibited the effect of VEGF165a
(c) and the effect of VEGF165b (d). e Graphs represent the mean of the scratched area in HPMEC treated with UO126 inhibitor at 24 h relative to
control. VEGF165a but not VEGF165b stimulation significantly diminished scratched area (p = 0.004) and was inhibited by UO126 (p = 0.03). Densitometry
and scratch assay analysed by Kruskal-Wallis test with post hoc Dunn’s analysis. TEER measurement analysed using two-way ANOVA and Bonferroni
post-test. All data were plotted as mean ± SEM (n = 3-6)





Fig. 5 (See legend on next page.)
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cells stimulated by VEGF165b (Fig. 6d). The inhibition of
those effects induced by both VEGF165a and VEGF165b by
L-NAME suggests that eNOS is not involved in the dif-
ferential effect on permeability induced by these VEGF
isoforms.
Discussion
The pulmonary endothelium is crucial to the regulation
of the passage of solutes and molecules between the
blood and the interstitial space of the lung, enabling
close proximity of the vascular bed to the alveolar space
for gaseous exchange to occur. Despite this, there is a
very limited understanding of the mechanisms involved
in the regulation of pulmonary endothelial cell (EC) bar-
rier function integrity, which is so essential for maintain-
ing this critical function of the lung.
Vascular endothelial growth factor (VEGF) was originally
described as both an angiogenic and a permeability factor
[39] and its effects have previously been studied using the
human umbilical vein endothelial cell (HUVEC) as the
archetypal EC. Large organ functional differences are
reflected in the variability of endothelial cell junction struc-
ture and composition particularly relevant in the functional
differences between the pulmonary and systemic circulation
(See figure on previous page.)
Fig. 5 HPMEC were stimulated with 20 ng/ml of VEGF165a, VEGF165b or without stimulation (Ctl/control). Representative western blots showing
VEGF stimulation at 5, 10 and 60 min plus loading control (α-tubulin) with densitometry (n = 3). a Western blot of phosphorylated p-38MAPK in
HPMEC. VEGF165a significantly increased phosphorylation of p-38MAPK at 5 and 10 min where VEGF165b only induced increased phosphorylation at
5 min. b & c: Measurement of HPMEC resistance by Endohm system. Dotted lines correspond to cell pre-incubated with p38 inhibitor SB203580.
SB203580 inhibited the effect of VEGF165a (b) and the effect of VEGF165b (c). d Graphs represent the mean of the scratched area for HPMEC treated with
SB203580 inhibitor at 24 h relative to control. VEGF165a but not VEGF165b stimulation significantly diminished scratched area (p = 0.002) and was inhib-
ited by SB203580 (p = 0.02). e Western blot of phosphorylated AKT in HPMEC. VEGF165a and VEGF165b significantly increased phosphorylation of p-Akt at
5 and 10 min. f & g Measurement of HPMEC resistance by Endohm system. Dotted lines correspond to cell pre-incubated with AKT inhibitor LY294002.
LY294002 inhibited the effect of VEGF165a (f) and the effect of VEGF165b (g). Densitometry and scratch assay analysed by Kruskal-Wallis test with post
hoc Dunn’s analysis. TEER measurement analysed using two-way ANOVA and Bonferroni post-test. All data were plotted as mean ± SEM (n= 3-6)
a b
c d
Fig. 6 a Representative Western blot of phosphorylated p-eNOS in HPMEC (n = 3). VEGF165a significantly increased phosphorylation of eNOS at 5
and 10 min in contrast with VEGF165b stimulation which did not induce any changes. b & c Measurement of HPMEC resistance by Endohm system. Dotted
lines correspond to cell pre-incubated with inhibitor. L-NAME inhibited the effect of VEGF165a (b) and the effect of VEGF165b (c). d Graphs represent the
mean of the scratched area for HPMEC treated with L-NAME inhibitor at 24 h relative to control. VEGF165a but not VEGF165b stimulation significantly
diminished scratched area (p = 0.009) and was inhibited by L-NAME (p = 0.04). Densitometry and scratch assay were analysed by Kruskal-Wallis test with
post hoc Dunn’s analysis. TEER measurement data were analysed using two-way ANOVA and Bonferroni post-test for multiple analysis. All data were
plotted as mean ± SEM (n = 3-6)
Ourradi et al. Respiratory Research  (2017) 18:116 Page 9 of 12
[40, 41]. To explore our hypothesis and its relationship to
previous clinical studies (5, 6) it was important to study the
response of human pulmonary microvascular endothelial
cell (HPMEC) to VEGF isoforms.
Among all the pathological processes involved in.
ARDS increases in lung vessel permeability are critical
and non-redundant [42]. The measurement of perme-
ability in this study has been undertaken only in-vitro
models with self-evident limitations [43]. Transport of
plasma proteins, cell and solutes across monolayers oc-
curs paracellularly via specialised endothelial cell-cell
junctions, or transcellularly by special transport mechan-
ism including transcytosis, via transcellular channels or
cell membrane transporter proteins.
Two types of inter-endothelial junction are present in
the endothelium, adherens and tight junctions, the
former being dominant in most vascular beds. The in-
tegrity of the adherens junction is particularly critical for
regulating paracellular permeability via homophilic ad-
hesions between VE-cadherin molecules [19, 20]. Dis-
ruptions of these domains lead to downstream events
that result in organisational changes in the actin cyto-
skeleton [44]. The transcellular pathway is responsible
for the transport of larger molecules such as albumin
across endothelial cell monolayers, classically via trans-
cellular pores associated with caveolae and lipid rafts
[45]. Traditionally these pathways have been considered
independent but there is now a body of evidence show-
ing interdependence [46]. Following on from this, the
in-vitro methods of measuring permeability that we have
used, TEER (thought to reflect only paracellular perme-
ability) and FITC-BSA (thought to only reflect transcel-
lular mechanism) are recognised to have influences from
crosstalk between both pathways [15].
We have demonstrated for the first time that
VEGF165a and VEGF165b induce differing effects on the
permeability of pulmonary microvascular endothelial
cells. Specifically, VEGF165a induced an increase and
VEGF165b a decrease in permeability. The receptor bind-
ing and dimerisation domains are intact in the VEGFxxxb
family of VEGF isoforms. However, in porcine aortic
endothelial cells, VEGF165b has been shown to stimulate
a unique pattern of VEGF-R2 tyrosine residue phosphor-
ylation, contrasting with those activated by conventional
isoforms suggesting activation of differing downstream
signalling pathways in addition to partial agonist activity
and changes in neuroplin-1 binding [22, 47, 48]. In this
study, differing phosphorylation kinetics were clearly ob-
served following stimulation by VEGF165a and VEGF165b
using what we considered to be physiologically relevant
concentrations of VEGF.
The differential effects of VEGF165a and VEGF165b on
the vascular permeability in addition to those we have pre-
viously shown and published on proliferation in HPMEC
(also repeated in the scratch experiments) and human al-
veolar epithelial cells offer a potential paradigm to explain
the apparent compartmentalisation of VEGF between the
alveolar and vascular space and the apparent disparity of
data relating to the role of VEGF in ARDS [5, 6, 12].
We identified that VEGF165a and VEGF165b lead to
differential functional outcomes with VEGF165a increas-
ing cell permeability in methods suggested to reflect
both para and transcellular permeability and VEGF165b
reducing paracellular permeability only. This suggested
that the differences were due to divergence of signalling
pathways and therefore potential targets for amelioration
of outcome e.g. reducing permeability whilst preserving
a pneumotropic effect. To verify this hypothesis, dif-
ferent protein inhibitors have been used to look at their
effect on the change in resistance reflecting the para-
cellular permeability pathway of pulmonary microvascu-
lar ECs.
The VEGF165a signalling pathways have been studied
extensively in HUVEC although studies in HPMEC are
limited [41]. We chose to use inhibitors of pMEK, P38
MAPK, PI3 kinase and eNOS proteins as these proteins
have been suggested to be involved in VEGF signalling
pathways and look at both permeability and proliferation/
migration in an attempt to identify a divergence in func-
tionality and thus an opportunity for selective inhibition.
The use of L-NAME (eNOS inhibitor) and LY294002
(PI3K inhibitor) on HPMEC inhibited the effect of both
VEGF165a and VEGF165b. Being part of the same sig-
nalling pathway these results suggest that VEGF cell
paracellular permeability involves the phosphoinositide
3-kinase–AKT pathway, which then further phosphory-
lates and activates endothelial nitric oxide synthase
(eNOS) [49]. Also, the inhibition of pMEK and p38
MAPK did not affect VEGF isoforms activity on the pro-
liferation and paracellular permeability pathway in
HPMEC. In summary, the inhibitors chosen did not
allow for the identification of specific differential path-
ways between VEGF165a and VEGF165b. Further studies
of other pathways are required in order to unravel the
molecules responsible for the differential permeability
effects of VEGF isoforms such as Src kinase pathway
and its role in the regulation of endothelial-barrier integ-
rity as demonstrated recently by Gao et al. [50].
Conclusion
HPMEC have specific signalling characteristics that are
probably adaptations to the unique pulmonary environ-
ment. In the context of ARDS, VEGF (from the alveolus)
may be a triggering component leading to further endo-
thelial dysfunction and failure of the ACM. The data
presented has shown that exposure of HPMEC to ex-
ogenous VEGF165a significantly increased endothelial
cell monolayer permeability which would lead to failure
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of the ACM barrier function, of particular significance in
the lung environment. On the other hand, depending on
the isoforms present, VEGF may also be a protective
agent, the data presented showing a decrease in perme-
ability with VEGF165b exposure. Further work will need to
be undertaken to clearly identify the divergence in the per-
meability signalling pathway induced by both isoforms
and the potential protective proprieties of VEGF165b.
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